Mathur Mathur¹* and Rupjyoti Das¹

¹Diploma Vascular Med (UK), Clinical Ph.D. Neurology (UK) and Fellow of European Academy of Neurology, Consultant Neurologist, Department of Clinical Neurology, GNRC Hospitals, Guwahati, India
²Head of Department and Senior Consultant, Department of Clinical Neurology, GNRC Hospitals, Guwahati, India

*Corresponding Author: Manik Mathur, Diploma Vascular Med (UK), Clinical Ph.D. Neurology (UK) and Fellow of European Academy of Neurology, Consultant Neurologist, Department of Clinical Neurology, GNRC Hospitals, Guwahati, India

Received: May 26, 2021; Published: June 29, 2021

Abstract

  Recent pandemic surge of Covid-19 has made it necessary to further understand a detailed neurological association with the virus in-relation to sub-clinical picture. Additionally, in the presence of a sweeping corona virus wave throughout the globe, pre-liminary studies have indicated a strong association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in addition to neuropsychiatric and neurological illness. Following a trivial research (clinical and paraclinical data), five major scenarios have been observed, namely, encephalopathies with no distinct MRI or CSF abnormalities, inflammatory CNS syndrome (including para-or-post-infections) with/out isolated myelitis, ischaemic strokes associated with pro-thrombotic state, peripheral neurological disorders such as Guillain-Barre syndrome and other miscellaneous neurological disorders. Therefore, an early recognition and understanding in the backdrop of neuropathology associated with COVID-19 is essential. Where hypercoagulability is a newfangled conduit in further complicating the pathogenesis to unreasonable levels. Here, a brief discussion on present neurology associated outcomes in COVID-19 scenario.

Keywords: SARS-CoV-2; COVID-19; Peripheral Nervous System (PNS)

References

1. Qureshi AI., et al. “Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients”. Stroke 3 (2021): 905-912.
2. Moriguchi T., et al. “A first case of meningitis/encephalitis associated with SARS-Coronavirus-2”. International Journal of Infectious Diseases 94 (2020): 55-58.
3. Helms J., et al. “Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients”. Critical Care1 (2020): 491.
4. Beyrouti R., et al. “Characteristics of ischaemic stroke associated with COVID-19”. Journal of Neurology, Neurosurgery, and Psychiatry 8 (2020): 889-891.
5. Toscano G., et al. “Guillain-Barre Syndrome Associated with SARS-CoV-2”. The New England Journal of Medicine 26 (2020): 2574-2576.
6. Franceschi, A.M., et al. “Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection”. AJNR American Journal of Neuroradiology7 (2020): 1173-1176.
7. Mahammedi, A., et al. “Imaging in Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Retrospective Observational Study”. Radiology (2020): 201933.
8. Qu, W., et al. “Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome”. Stem Cells Translational Medicine 9 (2020): 1007-1022.
9. Manson JJ., et al. “COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study”. Lancet Rheumatology (2020).
10. Hung EC., et al. “Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome”. Clinical Chemistry 12 (2003): 2108-2109.
11. Xu J., et al. “Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis”. Clinical Infectious Diseases 8 (2005): 1089-1096.
12. Ellul MA., et al. “Neurological associations of COVID-19”. Lancet Neurology9 (2020): 767-783.
13. Paterson RW., et al. “The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings”. Brain (2020).
14. Connors JM and JH Levy. “COVID-19 and its implications for thrombosis and anticoagulation”. Blood23 (2020): 2033-2040.
15. Terpos E., et al. “Hematological findings and complications of COVID-19”. American Journal of Hematology7 (2020): 834-847.
16. Bikdeli B., et al. “COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review”. Journal of the American College of Cardiology 23 (2020): 2950-2973.
17. Prompetchara E., et al. “Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic”. Asian Pacific Journal of Allergy and Immunology 1 (2020): 1-9.
18. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.

Citation

Citation: Mathur Mathur and Rupjyoti Das. “An Update on Neurological Outcome in Covid-19 Crisis: Hypercoagulability”. Acta Scientific Neurology 4.8 (2021): 70-72.

Copyright

Copyright: © 2021 Mathur Mathur and Rupjyoti Das. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.